What are Allakos Inc's Business Segments?
Allakos Inc is a clinical-stage biotechnology company that focuses on discovering and developing transformative antibody-based therapies to treat allergic, inflammatory and proliferative diseases. The company's primary focus is on developing therapies to address diseases with unmet need where most of the current treatments only manage symptoms or fail to address the underlying cause. Allakos' product pipeline comprises of monoclonal antibodies which target specific immune cells and proteins involved in inflammatory responses in the body.
Segments:
Allakos Inc has only one segment, which is drug development. The company is focused on developing new drugs utilizing its proprietary therapeutic platforms. The products and services offered by Allakos Inc fall under its drug development segment, with the aim of helping patients with unmet medical needs.
Products:
Allakos Inc is focused on developing monoclonal antibodies for the treatment of allergic, inflammatory and proliferative diseases. The company's products include:
1. AK002: AK002 is Allakos' lead drug candidate, which is being developed for the treatment of severe allergic diseases. It is a monoclonal antibody that targets mast cells, which are responsible for allergic reactions. Clinical trials have shown that AK002 can significantly reduce the symptoms of eosinophilic gastritis and eosinophilic esophagitis.
2. AK101: AK101 is a monoclonal antibody that targets the receptor molecule siglec-8, which plays a role in the regulation of mast cells and eosinophils responsible for inflammatory diseases. AK101 is being developed for the treatment of eosinophilic asthma and chronic rhinosinusitis with nasal polyposis.
3. AK301: AK301 is being developed for the treatment of inflammatory bowel disease (IBD). It is a monoclonal antibody that targets a protein called thymic stromal lymphopoietin (TSLP), which has been shown to play a role in the inflammation of the gastrointestinal tract in IBD.
Services:
Allakos Inc offers drug development services, such as research and development activities, which involve the discovery, optimization, and preclinical development of novel antibody-based therapeutics. The company leverages its proprietary platforms to develop new drugs that target specific immune cells and proteins in the body to fight allergic, inflammatory, and proliferative diseases.
In summary, Allakos Inc offers a range of monoclonal antibody products that target specific immune cells and proteins in the body to address life-threatening diseases. The company's products are in various stages of development, from preclinical to clinical stages, with the aim of meeting the needs of patients suffering from unmet medical needs. Allakos Inc's drug development services aim to help patients with various conditions in managing or treating their diseases.
|